In a phase 1 study in participants with Her2/neu-overexpressing cancers, administration of Flt3 before Her2/neu-specific peptide vaccine resulted in significantly higher IFN-γ-secreting Her2/neu-specific T cells. The gene discussed is FLT3; the disease is cancer.